Craig Leonardi
Overview
Explore the profile of Craig Leonardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
1949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Menter M, Mehta N, Lebwohl M, Gottlieb A, Mendelsohn A, Rozzo S, et al.
J Drugs Dermatol
. 2020 Aug;
19(8):703-708.
PMID: 32845115
Background: Metabolic syndrome (MetS) is the most prevalent comorbidity in psoriasis and increases the risk of cardiovascular disease, diabetes, and mortality. Assessment of impacts of biologic therapies on cardiometabolic risk...
12.
Leonardi C, Reich K, Foley P, Torii H, Gerdes S, Guenther L, et al.
Dermatol Ther (Heidelb)
. 2020 Mar;
10(3):431-447.
PMID: 32200512
Introduction: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for treatment of moderate-to-severe plaque psoriasis. Our objective was to evaluate the long-term efficacy and safety of ixekizumab...
13.
Grace E, Goldblum O, Renda L, Agada N, See K, Leonardi C, et al.
Dermatol Ther (Heidelb)
. 2019 Nov;
10(1):99-106.
PMID: 31734937
Introduction: Biologics used to treat moderate-to-severe plaque psoriasis may cause injection site reactions (ISRs) characterized by erythema, edema, itch, and sometimes pain. The Federal Adverse Event Reporting System (FAERS) is...
14.
Leonardi C, Maari C, Philipp S, Goldblum O, Zhang L, Burkhardt N, et al.
J Am Acad Dermatol
. 2018 May;
79(5):824-830.e2.
PMID: 29803904
Background: Psoriasis is a chronic disease that may require long-term treatment. Ixekizumab (IXE), which is a high-affinity monoclonal antibody that selectively targets interleukin 17A, is an approved therapy for patients...
15.
Zachariae C, Gordon K, Kimball A, Lebwohl M, Blauvelt A, Leonardi C, et al.
J Am Acad Dermatol
. 2018 Apr;
79(2):294-301.e6.
PMID: 29653208
Background: Ixekizumab has demonstrated improvement in patients with moderate-to-severe psoriasis by selectively targeting interleukin-17A, which is a proinflammatory cytokine that is important in the pathogenesis of psoriasis. Objective: To report...
16.
Shear N, Paul C, Blauvelt A, Gooderham M, Leonardi C, Reich K, et al.
J Drugs Dermatol
. 2018 Feb;
17(2):200-206.
PMID: 29462229
<p>BACKGROUND: Injection-site reactions (ISRs) are reported with biologic therapies. The objective of this study was to comprehensively characterize ISRs among moderate-to-severe psoriasis patients treated with ixekizumab, a high-affinity monoclonal antibody...
17.
Reich K, Leonardi C, Papp K, Gottlieb A, Thaci D, Schacht A, et al.
J Invest Dermatol
. 2017 Aug;
137(12):2642-2644.
PMID: 28780085
No abstract available.
18.
Al Sawah S, Foster S, Burge R, Amato D, Schacht A, Zhu B, et al.
J Med Econ
. 2017 Aug;
20(12):1224-1230.
PMID: 28760056
Background: Evidence of the cost-efficacy of ixekizumab for the treatment of moderate-to-severe plaque psoriasis (PsO) in the US is limited. Objective: To estimate the number needed to treat (NNT) and...
19.
Paul C, Leonardi C, Menter A, Reich K, Gold L, Warren R, et al.
Am J Clin Dermatol
. 2017 May;
18(4):591.
PMID: 28540589
No abstract available.
20.
Paul C, Leonardi C, Menter A, Reich K, Gold L, Warren R, et al.
Am J Clin Dermatol
. 2017 Feb;
18(3):405-411.
PMID: 28236223
Background: Fixed-combination calcipotriol 50 μg/g plus betamethasone 0.5 mg/g (Cal/BD) aerosol foam is a new topical treatment for psoriasis. Although moderate-to-severe psoriasis is typically treated with systemic/biologic therapies, a topical...